<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hypomagnesemia: Causes of hypomagnesemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hypomagnesemia: Causes of hypomagnesemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hypomagnesemia: Causes of hypomagnesemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan S L Yu, MB, BChir
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 12, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H8658039">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomagnesemia is a common entity occurring in up to 12 percent of hospitalized patients [
         <a href="#rid1">
          1
         </a>
         ]. The incidence rises to as high as 60 to 65 percent in patients in an intensive care setting in which nutrition, diuretics, hypoalbuminemia, and aminoglycosides may play important roles [
         <a href="#rid2">
          2-5
         </a>
         ]. In addition, serum magnesium concentration is a quantitative trait with substantial polygenic heritability, and a number of genome-wide association studies (GWAS) have identified candidate loci associated with low serum magnesium levels [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
         There are two major mechanisms by which hypomagnesemia can be induced: gastrointestinal or renal losses  (
         <a class="graphic graphic_table graphicRef98056" href="/z/d/graphic/98056.html" rel="external">
          table 1
         </a>
         ). Regardless of the cause, hypomagnesemia begins to occur after a relatively small magnesium deficit because there is little rapid exchange of extracellular magnesium with the much larger bone and cell stores.
        </p>
        <p>
         Hypomagnesemia is often associated with hypokalemia (due to urinary potassium wasting) and hypocalcemia (due both to lower parathyroid hormone secretion and end-organ resistance to its effect). (See
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion"
         </a>
         .)
        </p>
        <p>
         The major causes of hypomagnesemia will be reviewed in this topic. The regulation of magnesium balance, the signs and symptoms of hypomagnesemia, and the evaluation and treatment of patients with hypomagnesemia are presented elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/844.html" rel="external">
          "Regulation of magnesium balance"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/834.html" rel="external">
          "Hypomagnesemia: Evaluation and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8658046">
         <span class="h1">
          GASTROINTESTINAL LOSSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal secretions contain some magnesium, and potential losses are continuous and not regulated. Although the obligatory losses are not large, marked dietary deprivation can lead to progressive magnesium depletion.
        </p>
        <p>
         Magnesium losses from both the upper and lower gastrointestinal tract can induce hypomagnesemia. In general, magnesium depletion is more commonly due to diarrhea than to vomiting [
         <a href="#rid5">
          5
         </a>
         ]. This is because the magnesium content of lower tract secretions is significantly higher (up to 15 mEq/L versus approximately 1 mEq/L for upper tract). Common settings in which hypomagnesemia may be seen include acute or chronic diarrhea, malabsorption and steatorrhea, and small bowel bypass surgery.
        </p>
        <p>
         In addition, hypomagnesemia with secondary hypocalcemia can be produced by a familial disorder characterized by a selective defect in magnesium absorption (primary intestinal hypomagnesemia). This disease presents in the neonatal period with hypocalcemia that is responsive to magnesium administration [
         <a href="#rid9">
          9
         </a>
         ]. In some instances, the defect appears to have an X-linked recessive inheritance, but others have described autosomally recessive inheritance with linkage to chromosome 9 [
         <a href="#rid10">
          10
         </a>
         ]. The autosomal recessive form is caused by mutations in the TRPM6 gene [
         <a href="#rid11">
          11-15
         </a>
         ]. The encoded protein, which is expressed both by intestinal epithelia and by the renal distal convoluted tubule, functions as an apical magnesium entry channel [
         <a href="#rid16">
          16
         </a>
         ]. Thus, patients with this disorder have not only decreased intestinal magnesium absorption, but also inappropriate renal magnesium wasting.
        </p>
        <p>
         Hypomagnesemia can also be seen in acute pancreatitis. The mechanism of hypomagnesemia is presumably similar to the mechanism partially responsible for hypocalcemia in acute pancreatitis: saponification of magnesium and calcium in necrotic fat [
         <a href="#rid17">
          17
         </a>
         ]. The degree of hypocalcemia may be exacerbated by the hypomagnesemia, which can both lower parathyroid hormone secretion and induce end-organ resistance to its effect. (See
         <a class="medical medical_review" href="/z/d/html/840.html" rel="external">
          "Etiology of hypocalcemia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8658053">
         <span class="h2">
          Proton pump inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomagnesemia, usually with hypocalcemia, has been described in case reports with the chronic use of
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         (usually for more than one year) and other proton pump inhibitors (PPIs) [
         <a href="#rid18">
          18-21
         </a>
         ]. The association of PPIs with lower serum magnesium has also been described in population studies [
         <a href="#rid22">
          22-25
         </a>
         ]. The best data come from a large cohort of 11,490 patients admitted to the intensive care unit at a single center [
         <a href="#rid22">
          22
         </a>
         ]. In this study, the relationship between PPI use and magnesium varied by whether patients concurrently used diuretics (see
         <a class="medical medical_review" href="/z/d/html/2335.html" rel="external">
          "Effect of diuretics on magnesium handling by the kidney"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients taking diuretics, concurrent use of PPIs was associated with a 0.028 mg/dL (0.011 mmol/L) lower adjusted serum magnesium. In addition, the prevalence of hypomagnesemia (defined as a serum magnesium less than 1.6 mg/dL [0.66 mmol/L]) was significantly higher in patients taking both drugs as compared with those who only used diuretics (15.6 versus 11 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients not taking diuretics, use of PPIs was not associated with the serum magnesium or the prevalence of hypomagnesemia.
        </p>
        <p>
        </p>
        <p>
         In a smaller study of 402 inpatients with hypomagnesemia and matched controls, proton pump inhibitors were not associated with hypomagnesemia [
         <a href="#rid23">
          23
         </a>
         ]. However, duration of use was not examined, and most patients were not taking diuretics; therefore, these findings are potentially consistent with those of the larger cohort study. A meta-analysis of studies through 2014 reported a pooled odds ratio for PPI-associated hypomagnesemia of 1.78 (95% CI 1.08-2.92), although there was substantial heterogeneity among the included studies [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         The presumed mechanism is impaired absorption of magnesium by intestinal epithelial cells caused by PPI-induced inhibition of transient receptor potential melastatin-6 (TRPM6) and TRPM7 channels [
         <a href="#rid26">
          26
         </a>
         ]. Renal losses are not likely to be involved, since urinary magnesium excretion is appropriately low in patients with hypomagnesemia due to PPIs [
         <a href="#rid20">
          20,21
         </a>
         ]. Some patients have inappropriately low serum parathyroid hormone levels [
         <a href="#rid19">
          19
         </a>
         ], a finding that is well described in patients with hypomagnesemia due to other causes. (See
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion", section on 'Calcium metabolism'
         </a>
         .)
        </p>
        <p>
         In March 2011, the United States Food and Drug Administration (FDA) issued a safety warning suggesting that, in patients expected to be on PPIs for long periods of time and in those taking other medications associated with hypomagnesemia as described below (eg, diuretics), providers measure serum magnesium levels prior to initiation of PPI therapy and periodically during treatment [
         <a href="#rid27">
          27
         </a>
         ]. The hypomagnesemia can be partially or completely corrected by high-dose oral magnesium supplementation [
         <a href="#rid19">
          19-21
         </a>
         ]. Hypomagnesemia resolves with cessation of PPI therapy [
         <a href="#rid18">
          18,19,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8658060">
         <span class="h1">
          RENAL LOSSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary magnesium losses can occur via a variety of either acquired or intrinsic mechanisms. (See
         <a class="medical medical_review" href="/z/d/html/844.html" rel="external">
          "Regulation of magnesium balance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8658067">
         <span class="h2">
          Medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both loop and thiazide diuretics can inhibit net magnesium reabsorption, while potassium-sparing diuretics may enhance magnesium transport and lower magnesium excretion. The degree of hypomagnesemia induced by loop and thiazide diuretics is generally mild, in part because the associated volume contraction will tend to increase proximal sodium, water, and magnesium reabsorption. A more detailed review of how these changes might occur is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2335.html" rel="external">
          "Effect of diuretics on magnesium handling by the kidney"
         </a>
         .)
        </p>
        <p>
         In addition to loop and thiazide diuretics, many nephrotoxic drugs can produce urinary magnesium wasting [
         <a href="#rid28">
          28
         </a>
         ], including but not limited to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aminoglycoside antibiotics (see
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Nephrotoxicity'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amphotericin B (see
         <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">
          "Amphotericin B nephrotoxicity"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         (see
         <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">
          "Cisplatin nephrotoxicity"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">
          Pentamidine
         </a>
         (see
         <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">
          "Overview of kidney disease in patients with HIV", section on 'Electrolyte disorders'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calcineurin inhibitors (see
         <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">
          "Cyclosporine and tacrolimus nephrotoxicity"
         </a>
         and
         <a class="local">
          'Posttransplant patients'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibodies targeting the epidermal growth factor (EGF) receptor (
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">
          "Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'Anti-EGFR monoclonal antibodies'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The impairment in loop and distal magnesium reabsorption may occur prior to the onset of, and may persist after the resolution of, the acute tubular necrosis and acute kidney injury (AKI) associated with these nephrotoxins. Studies in the rat, for example, have shown a dose-related and rapidly reversible decrease in renal tubular reabsorption of magnesium and calcium (but not sodium and potassium) within 60 minutes of beginning an infusion of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ]. The hypermagnesuria in this setting can be striking, and the resulting hypomagnesemia may be sufficient to produce hypocalcemia. With
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         therapy, a reduction in gastrointestinal magnesium absorption may also contribute to the hypomagnesemia [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8658074">
         <span class="h2">
          Volume expansion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Expansion of the extracellular fluid volume, by reducing reabsorption of sodium and water, can decrease passive magnesium transport. Mild hypomagnesemia may ensue if this is sustained, as in primary aldosteronism. (See
         <a class="medical medical_review" href="/z/d/html/140.html" rel="external">
          "Pathophysiology and clinical features of primary aldosteronism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8658081">
         <span class="h2">
          Alcohol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomagnesemia is common in patients with an alcohol use disorder who are admitted to the hospital; in one study, for example, the prevalence was 30 percent [
         <a href="#rid32">
          32
         </a>
         ]. Excessive urinary excretion of magnesium occurred in 18 of the 38 patients with hypomagnesemia. The defect in urinary excretion appears to reflect alcohol-induced tubular dysfunction that is reversible within four weeks of abstinence [
         <a href="#rid33">
          33
         </a>
         ]. This effect is relatively modest, and other factors are also thought to contribute to hypomagnesemia in these patients, including dietary deficiency, acute pancreatitis, and diarrhea.
        </p>
        <p class="headingAnchor" id="H8658088">
         <span class="h2">
          Uncontrolled diabetes mellitus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomagnesemia is not uncommon in patients with uncontrolled diabetes mellitus; it appears to be associated with increased urinary magnesium excretion that is reversed by correction of the hyperglycemia with insulin [
         <a href="#rid5">
          5,34,35
         </a>
         ]. It has been proposed, although not proven, that hypomagnesemia may impair glucose disposal and may play a role in the pathogenesis of some of the complications of diabetes.
        </p>
        <p class="headingAnchor" id="H3773498229">
         <span class="h2">
          Posttransplant patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomagnesemia is common in patients who have received solid organ transplants and may be an important risk factor for new-onset diabetes mellitus after transplantation [
         <a href="#rid36">
          36-38
         </a>
         ].
        </p>
        <p>
         Hypomagnesemia after transplantation is attributed to renal magnesium wasting [
         <a href="#rid36">
          36
         </a>
         ] and is primarily caused by treatment with calcineurin inhibitors, which are known to downregulate TRPM6 [
         <a href="#rid39">
          39
         </a>
         ]. These drugs may also increase claudin-14 expression, which would inhibit paracellular magnesium transport [
         <a href="#rid40">
          40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/844.html" rel="external">
          "Regulation of magnesium balance"
         </a>
         .)
        </p>
        <p>
         The incidence of hypomagnesemia after kidney transplantation in patients treated with
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         may be as high as 43 percent [
         <a href="#rid41">
          41
         </a>
         ], which is considerably higher than in patients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid42">
          42
         </a>
         ]. In such patients who are converted from a calcineurin inhibitor to a mammalian (mechanistic) target of rapamycin (mTOR) inhibitor, serum magnesium levels increase by approximately 0.2 mg/dL, with a concomitant decrease in the fractional excretion of magnesium [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8658095">
         <span class="h2">
          Hypercalcemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with hypercalcemia due, for example, to hyperparathyroidism can develop mild hypomagnesemia. This finding results at least in part from the fact that calcium and magnesium functionally compete for transport in the thick ascending limb of the loop of Henle. A variety of mechanisms may contribute to the reduction in magnesium reabsorption resulting from hypercalcemia. One well-established mechanism is mediated by the basolateral calcium-sensing receptor (CaSR) in the thick ascending limb:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calcium binds to the basolateral CaSR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         This leads to generation of prostaglandins and cytochrome P450 metabolites in the cell, which inhibit the apical potassium channel (ROMK) [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhibition of ROMK inhibits sodium chloride reabsorption in the thick ascending limb and reduces paracellular magnesium and calcium reabsorption  (
         <a class="graphic graphic_figure graphicRef94326" href="/z/d/graphic/94326.html" rel="external">
          figure 1
         </a>
         ). Inhibition of ROMK in this nephron segment resulting from stimulation of the CaSR is the mechanism underlying type V Bartter syndrome. Thus, hypercalcemia can produce a Bartter-like phenotype. (See
         <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">
          "Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In addition, stimulation of the CaSR decreases paracellular permeability of the thick ascending limb to both magnesium and calcium [
         <a href="#rid46">
          46
         </a>
         ], likely due to increased expression of claudin-14 [
         <a href="#rid47">
          47,48
         </a>
         ], which negatively regulates claudin-16 and claudin-19. (See
         <a class="local">
          'Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8658102">
         <span class="h2">
          Other acquired tubular dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Magnesium wasting can be seen as part of the tubular dysfunction associated with recovery from acute tubular necrosis, following kidney transplantation, or during a postobstructive diuresis.
        </p>
        <p class="headingAnchor" id="H8658109">
         <span class="h2">
          Familial renal magnesium wasting
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary renal magnesium wasting is an unusual disorder that may present sporadically or as a familial disease [
         <a href="#rid49">
          49-53
         </a>
         ]. Several types have been recognized [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         The diagnosis of primary renal magnesium wasting is one of
         <strong>
          exclusion
         </strong>
         . It is established by the demonstration of inappropriately high urinary magnesium excretion in the absence of any other apparent cause. (See
         <a class="medical medical_review" href="/z/d/html/834.html" rel="external">
          "Hypomagnesemia: Evaluation and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8658116">
         <span class="h3">
          Gitelman and Bartter syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gitelman syndrome is the most common form of familial renal magnesium wasting and is usually associated with salt wasting, hypokalemic metabolic alkalosis, and
         <strong>
          hypocalciuria
         </strong>
         . It is caused by recessive mutations in the gene coding for the thiazide-sensitive sodium chloride cotransporter (
         <em>
          SLC12A3
         </em>
         ). Although the hypokalemia in this syndrome is usually attributed to decreased sodium chloride transport, direct effects of hypomagnesemia may also contribute [
         <a href="#rid55">
          55
         </a>
         ]. The hypomagnesemia in Gitelman syndrome is significantly more marked than that observed with thiazide administration. Bartter syndrome, particularly the late-onset cases due to mutations in
         <em>
          CLCNKB
         </em>
         (Bartter syndrome type 3) that resemble Gitelman syndrome, may also present with hypomagnesemia due to defective reabsorption in the thick ascending limb [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">
          "Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1498217874">
         <span class="h3">
          EAST (SeSAME) syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         EAST syndrome (also known as SeSAME syndrome) is an autosomal recessive disorder that presents in infancy with epilepsy, ataxia, sensorineural deafness, intellectual disability, and a renal salt-losing tubulopathy that resembles Gitelman syndrome and manifests as hypokalemic metabolic alkalosis with hypomagnesemia [
         <a href="#rid57">
          57,58
         </a>
         ]. This syndrome is caused by loss-of-function mutations in the gene encoding the potassium channel, KCNJ10 (Kir4.1), which is expressed on the basolateral membrane of the distal convoluted tubule and regulates expression of the thiazide-sensitive sodium chloride cotransporter [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8658123">
         <span class="h3">
          Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)
         </span>
         <span class="headingEndMark">
          —
         </span>
         This form of primary renal magnesium wasting is autosomal recessive and associated with
         <strong>
          hypercalciuria
         </strong>
         ; affected patients usually present in childhood or adolescence with symptomatic hypocalcemia [
         <a href="#rid60">
          60-64
         </a>
         ]. Recurrent nephrolithiasis and nephrocalcinosis are also seen, and progression to kidney function impairment and an acidification defect are common. The problem with acidification has been attributed to defective ammonia transfer to the deep nephrons and impaired medullary hydrogen ion secretion due to nephrocalcinosis [
         <a href="#rid65">
          65
         </a>
         ]. Affected patients may also have polyuria and polydipsia due to nephrogenic diabetes insipidus [
         <a href="#rid60">
          60,64
         </a>
         ].
        </p>
        <p>
         Mutations in the claudin-16 gene (also known as paracellin-1) are the major cause of FHHNC [
         <a href="#rid15">
          15,64,66-70
         </a>
         ]. Claudin-16 is a tight junction protein that facilitates the passive, paracellular reabsorption of both magnesium and calcium in the thick ascending limb of the loop of Henle. Some of these patients present with hypokalemia due to either secondary hyperaldosteronism and/or direct effects of hypomagnesemia on potassium transport.
        </p>
        <p>
         FHHNC may occasionally be due to mutations in claudin-19 [
         <a href="#rid71">
          71
         </a>
         ]. In addition to hypomagnesemia, nephrolithiasis, and nephrocalcinosis, such patients have ocular involvement [
         <a href="#rid72">
          72
         </a>
         ], which may include macular colobomata, nystagmus, and myopia.
        </p>
        <p class="headingAnchor" id="H8658130">
         <span class="h3">
          Na-K-ATPase mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         A gene responsible for autosomal dominant isolated renal magnesium wasting in two unrelated Dutch families has been mapped to a region on chromosome 11q23 [
         <a href="#rid73">
          73
         </a>
         ]. The abnormality in this disorder appears to be a dominant negative mutation in the gene encoding the gamma subunit of Na-K-ATPase, resulting in misrouting of the protein [
         <a href="#rid74">
          74,75
         </a>
         ]. This may mimic the magnesuric effects of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         . In addition, de novo heterozygous loss-of-function mutations in the
         <em>
          ATP1A1
         </em>
         gene, which encodes the a1 subunit of the Na-K-ATPase, have been described in three infants with severe hypomagnesemia due to renal magnesium wasting, refractory seizures, and intellectual disability [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="local">
          'Medications'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H8658137">
         <span class="h3">
          Voltage-gated potassium channel
         </span>
         <span class="headingEndMark">
          —
         </span>
         A mutation in the gene (KCNA1) that encodes the voltage-gated potassium channel (Kv1.1) is the cause of isolated autosomal dominant hypomagnesemia discovered in a large Brazilian family [
         <a href="#rid77">
          77
         </a>
         ]. This channel colocalizes with the magnesium channel TRPM6 in the distal collecting tubules. Wild type Kv1.1 appears to control TRPM6 magnesium reabsorption via the creation of an appropriate potential across the luminal membrane.
        </p>
        <p class="headingAnchor" id="H8658144">
         <span class="h3">
          Hepatocyte nuclear factor-1-beta gene mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomagnesemia and renal magnesium wasting have been reported in children with known mutations in the hepatocyte nuclear factor-1-beta (HNF-1-beta) gene [
         <a href="#rid78">
          78
         </a>
         ]. The prevalence of hypomagnesemia in such patients increases with age (100 percent by age 13.5 to 18 years) and is associated with a more generalized dysfunction of the distal convoluted tubule that resembles Gitelman syndrome [
         <a href="#rid79">
          79
         </a>
         ]. HNF-1-beta is a transcription factor that regulates the expression of the gamma subunit of Na-K-ATPase and the potassium channel Kir5.1 [
         <a href="#rid80">
          80
         </a>
         ]. These findings suggest that some inactivating mutations of HNF-1-beta can inhibit the Na-K-ATPase and Kir5.1, thereby causing hypomagnesemia/Gitelman-like syndrome, in association with early-onset diabetes and kidney malformations that include multicystic dysplastic disease and obstructive uropathy. (See
         <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">
          "Classification of diabetes mellitus and genetic diabetic syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8658151">
         <span class="h3">
          Epidermal growth factor gene mutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidermal growth factor (EGF) appears to stimulate distal tubular magnesium reabsorption by binding to a receptor on the basolateral membrane and activating the magnesium channel TRPM6 in the apical membrane. A point mutation in pro-EGF leads to impaired basolateral membrane sorting, inadequate stimulation of renal EGF receptor, insufficient activation of the magnesium channel, and causes isolated autosomal recessive renal magnesium wasting [
         <a href="#rid81">
          81,82
         </a>
         ]. A similar inhibition of the EGF receptor likely underlies the effects of
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         and other EGF receptor inhibitors on magnesium transport as previously mentioned [
         <a href="#rid81">
          81,82
         </a>
         ]. (See
         <a class="local">
          'Medications'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3528966858">
         <span class="h3">
          PCBD1 mutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         PCBD1 (pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor-1 homeobox A) is a protein that acts as an enzyme to regenerate tetrahydrobiopterin, which is a cofactor for phenylalanine hydroxylase. Homozygous mutations in
         <em>
          PCBD1
         </em>
         in neonates causes transient hyperphenylalaninemia. In addition, PCBD1 acts as a dimerization cofactor for the transcription factor, hepatocyte nuclear factor-1-beta (HNF1B). Homozygous mutations in
         <em>
          PCBD1
         </em>
         in adults have been reported to be associated with hypomagnesemia, renal magnesium wasting, and maturity-onset diabetes of the young, mimicking the effect of
         <em>
          HNF1B
         </em>
         mutations [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1793.html" rel="external">
          "Classification of diabetes mellitus and genetic diabetic syndromes", section on 'Hepatocyte nuclear factor-1-beta'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8658158">
         <span class="h3">
          Cyclin M2 mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the cyclin M2 (CNNM2) gene have been implicated in two families with dominant isolated renal magnesium wasting [
         <a href="#rid84">
          84
         </a>
         ]. CNNM2 encodes a transmembrane protein that is localized to the basolateral membrane of the thick ascending limb and distal convoluted tubule; it functions either as a magnesium channel [
         <a href="#rid85">
          85
         </a>
         ] or magnesium-sensitive sodium channel and is upregulated under conditions of magnesium deficiency.
        </p>
        <p class="headingAnchor" id="H8658165">
         <span class="h1">
          MISCELLANEOUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomagnesemia has been described in a number of other settings. The following is a partial list of potential causes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravascular chelation can lead to hypomagnesemia and has been described in the following settings:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Following surgery, at least in part due to chelation by circulating free fatty acids [
         <a href="#rid86">
          86
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         After
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         therapy of cytomegalovirus chorioretinitis, often in association with hypocalcemia [
         <a href="#rid87">
          87
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ionized hypomagnesemia during liver transplantation due to transfusion of citrate-rich blood products in the absence of adequate hepatic function to metabolize the citrate [
         <a href="#rid88">
          88
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypomagnesemia can occur as part of the "hungry bone" syndrome in which there is increased magnesium uptake by renewing bone following parathyroidectomy for hyperparathyroidism, thyroidectomy for hyperthyroidism, or correction of severe metabolic acidosis [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2070.html" rel="external">
          "Hungry bone syndrome following parathyroidectomy in patients with end-stage kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypomagnesemia has been found in up to 10 percent of patients placed on an extremely high-fat diet to induce ketogenesis as the therapy of intractable epilepsy. The mechanism of this effect is not clear but may result from malabsorption of magnesium [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2214.html" rel="external">
          "Evaluation and management of drug-resistant epilepsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypomagnesemia due solely to dietary deprivation is exceedingly rare, since nearly all foods contain some magnesium, and renal adaptation to conserve magnesium is highly efficient. Magnesium deficiency has been described rarely with protein-calorie malnutrition [
         <a href="#rid91">
          91
         </a>
         ]. In addition, it may occur in patients with an alcohol use disorder (see
         <a class="local">
          'Alcohol'
         </a>
         above), in whom decreased food intake in combination with renal magnesium losses seems to be responsible. Hypomagnesemia is also observed in patients receiving
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         , likely due to refeeding syndrome [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypomagnesemia, in combination with hypertension and dyslipidemia, was described in a kindred with a mutation in mitochondrial tRNA [
         <a href="#rid93">
          93
         </a>
         ]. The mutation likely resulted in multiple and varied physiologic disruptions because of its effect on energy consumption. With respect to low magnesium levels, distal convoluted tubule cells could be adversely affected because magnesium reabsorption requires significant energy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypomagnesemia has been associated with leptospirosis and may be due at least in part to urinary magnesium wasting [
         <a href="#rid94">
          94,95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8658172">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Hypomagnesemia is a common entity occurring in up to 12 percent of hospitalized patients. The incidence rises to as high as 60 to 65 percent in patients in an intensive care setting. There are two major mechanisms by which hypomagnesemia can be induced: gastrointestinal or renal losses  (
         <a class="graphic graphic_table graphicRef98056" href="/z/d/graphic/98056.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal losses
         </strong>
         – Gastrointestinal secretions contain some magnesium. Although the obligatory losses are not large, marked dietary deprivation can lead to progressive magnesium depletion. Magnesium losses from both the upper and lower gastrointestinal tract can induce hypomagnesemia. Common settings in which hypomagnesemia may be seen include acute or chronic diarrhea, malabsorption and steatorrhea, and small bowel bypass surgery. Hypomagnesemia can also be seen in acute pancreatitis. (See
         <a class="local">
          'Gastrointestinal losses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proton pump inhibitor use
         </strong>
         – Hypomagnesemia has been described with the chronic use of proton pump inhibitors (PPIs), usually for more than one year, and is due to impaired intestinal absorption. The United States Food and Drug Administration (FDA) issued a safety warning suggesting that, in patients expected to be on these drugs for long periods of time and in those taking other medications associated with hypomagnesemia (eg, diuretics), providers should measure serum magnesium levels prior to initiation of therapy and periodically during treatment. (See
         <a class="local">
          'Proton pump inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal losses
         </strong>
         – Urinary magnesium losses can occur via a variety of either acquired or intrinsic mechanisms. These include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medications, including loop and thiazide diuretics and various potential nephrotoxins (see
         <a class="local">
          'Medications'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sustained expansion of the extracellular fluid volume, as with primary aldosteronism (see
         <a class="local">
          'Volume expansion'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alcohol use (see
         <a class="local">
          'Alcohol'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Uncontrolled diabetes mellitus (see
         <a class="local">
          'Uncontrolled diabetes mellitus'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypercalcemia, as in patients with primary hyperparathyroidism (see
         <a class="local">
          'Hypercalcemia'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recovery from acute kidney injury (AKI) and following kidney transplantation (see
         <a class="local">
          'Other acquired tubular dysfunction'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Familial renal magnesium wasting, such as with Gitelman syndrome (see
         <a class="local">
          'Familial renal magnesium wasting'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H96091283">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Zalman Agus, MD, and Gunjeet K Kala Ahluwalia, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wong ET, Rude RK, Singer FR, Shaw ST Jr. A high prevalence of hypomagnesemia and hypermagnesemia in hospitalized patients. Am J Clin Pathol 1983; 79:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chernow B, Bamberger S, Stoiko M, et al. Hypomagnesemia in patients in postoperative intensive care. Chest 1989; 95:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desai TK, Carlson RW, Geheb MA. Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting. Am J Med 1988; 84:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryzen E. Magnesium homeostasis in critically ill patients. Magnesium 1989; 8:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med 2005; 20:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer TE, Verwoert GC, Hwang SJ, et al. Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. PLoS Genet 2010; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang X, Glessner J, Tin A, et al. Genome-wide association study reveals two loci for serum magnesium concentrations in European-American children. Sci Rep 2015; 5:18792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tin A, Köttgen A, Folsom AR, et al. Genetic loci for serum magnesium among African-Americans and gene-environment interaction at MUC1 and TRPM6 in European-Americans: the Atherosclerosis Risk in Communities (ARIC) study. BMC Genet 2015; 16:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paunier L, Radde IC, Kooh SW, et al. Primary hypomagnesemia with secondary hypocalcemia in an infant. Pediatrics 1968; 41:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walder RY, Shalev H, Brennan TM, et al. Familial hypomagnesemia maps to chromosome 9q, not to the X chromosome: genetic linkage mapping and analysis of a balanced translocation breakpoint. Hum Mol Genet 1997; 6:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002; 31:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 2002; 31:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang CL. The transient receptor potential superfamily of ion channels. J Am Soc Nephrol 2004; 15:1690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlingmann KP, Sassen MC, Weber S, et al. Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. J Am Soc Nephrol 2005; 16:3061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guran T, Akcay T, Bereket A, et al. Clinical and molecular characterization of Turkish patients with familial hypomagnesaemia: novel mutations in TRPM6 and CLDN16 genes. Nephrol Dial Transplant 2012; 27:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voets T, Nilius B, Hoefs S, et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004; 279:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryzen E, Rude RK. Low intracellular magnesium in patients with acute pancreatitis and hypocalcemia. West J Med 1990; 152:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012; 36:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009; 151:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008; 69:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danziger J, William JH, Scott DJ, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013; 83:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koulouridis I, Alfayez M, Tighiouart H, et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis 2013; 62:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park CH, Kim EH, Roh YH, et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One 2014; 9:e112558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zipursky J, Macdonald EM, Hollands S, et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. PLoS Med 2014; 11:e1001736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perazella MA. Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int 2013; 83:553.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm (Accessed on March 08, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah GM, Kirschenbaum MA. Renal magnesium wasting associated with therapeutic agents. Miner Electrolyte Metab 1991; 17:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-Amer N, Priel E, Karlish SJD, et al. Hypermagnesuria in Humans Following Acute Intravenous Administration of Digoxin. Nephron 2018; 138:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster JE, Harpur ES, Garland HO. An investigation of the acute effect of gentamicin on the renal handling of electrolytes in the rat. J Pharmacol Exp Ther 1992; 261:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lajer H, Kristensen M, Hansen HH, et al. Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol 2005; 55:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elem Med Biol 1995; 9:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Marchi S, Cecchin E, Basile A, et al. Renal tubular dysfunction in chronic alcohol abuse--effects of abstinence. N Engl J Med 1993; 329:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med 1996; 156:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White JR Jr, Campbell RK. Magnesium and diabetes: a review. Ann Pharmacother 1993; 27:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos EL, Barri YM, Kubilis P, et al. Hypomagnesemia in renal transplant patients: improvement over time and association with hypertension and cyclosporine levels. Clin Transplant 1995; 9:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Laecke S, Van Biesen W, Verbeke F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009; 9:2140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang JW, Famure O, Li Y, Kim SJ. Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation. J Am Soc Nephrol 2016; 27:1793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nijenhuis T, Hoenderop JG, Bindels RJ. Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 2004; 15:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gong Y, Hou J. Claudin-14 underlies Ca⁺⁺-sensing receptor-mediated Ca⁺⁺ metabolism via NFAT-microRNA-based mechanisms. J Am Soc Nephrol 2014; 25:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navaneethan SD, Sankarasubbaiyan S, Gross MD, et al. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 2006; 38:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Fructuoso AI, Santín Cantero JM, Pérez Flores I, et al. Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen. Transplant Proc 2010; 42:3047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 1996; 271:C103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W, Lu M, Balazy M, Hebert SC. Phospholipase A2 is involved in mediating the effect of extracellular Ca2+ on apical K+ channels in rat TAL. Am J Physiol 1997; 273:F421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loupy A, Ramakrishnan SK, Wootla B, et al. PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest 2012; 122:3355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gong Y, Renigunta V, Himmerkus N, et al. Claudin-14 regulates renal Ca⁺⁺ transport in response to CaSR signalling via a novel microRNA pathway. EMBO J 2012; 31:1999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimke H, Desai P, Borovac J, et al. Activation of the Ca(2+)-sensing receptor increases renal claudin-14 expression and urinary Ca(2+) excretion. Am J Physiol Renal Physiol 2013; 304:F761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans RA, Carter JN, George CR, et al. The congenital "magnesium-losing kidney". Report of two patients. Q J Med 1981; 50:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geven WB, Monnens LA, Willems JL. Magnesium metabolism in childhood. Miner Electrolyte Metab 1993; 19:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman RM, Pearson E. Hypomagnesemia of unknown etiology. Am J Med 1966; 41:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Runeberg L, Collan Y, Jokinen EJ, et al. Hypomagnesemia due to renal disease of unknown etiology. Am J Med 1975; 59:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booth BE, Johanson A. Hypomagnesemia due to renal tubular defect in reabsorption of magnesium. J Pediatr 1974; 85:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konrad M, Weber S. Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol 2003; 14:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamel KS, Harvey E, Douek K, et al. Studies on the pathogenesis of hypokalemia in Gitelman's syndrome: role of bicarbonaturia and hypomagnesemia. Am J Nephrol 1998; 18:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seys E, Andrini O, Keck M, et al. Clinical and Genetic Spectrum of Bartter Syndrome Type 3. J Am Soc Nephrol 2017; 28:2540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bockenhauer D, Feather S, Stanescu HC, et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 2009; 360:1960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scholl UI, Choi M, Liu T, et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci U S A 2009; 106:5842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang C, Wang L, Zhang J, et al. KCNJ10 determines the expression of the apical Na-Cl cotransporter (NCC) in the early distal convoluted tubule (DCT1). Proc Natl Acad Sci U S A 2014; 111:11864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praga M, Vara J, González-Parra E, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int 1995; 47:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson JC, Jones CL, Powell HR, et al. Familial hypomagnesaemia--hypercalciuria leading to end-stage renal failure. Pediatr Nephrol 1995; 9:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benigno V, Canonica CS, Bettinelli A, et al. Hypomagnesaemia-hypercalciuria-nephrocalcinosis: a report of nine cases and a review. Nephrol Dial Transplant 2000; 15:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller D, Kausalya PJ, Bockenhauer D, et al. Unusual clinical presentation and possible rescue of a novel claudin-16 mutation. J Clin Endocrinol Metab 2006; 91:3076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konrad M, Hou J, Weber S, et al. CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2008; 19:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez-Soriano J, Vallo A. Pathophysiology of the renal acidification defect present in the syndrome of familial hypomagnesaemia-hypercalciuria. Pediatr Nephrol 1994; 8:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon DB, Lu Y, Choate KA, et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 1999; 285:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard A, Jeunemaitre X, Coudol P, et al. Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. Kidney Int 2001; 59:2206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber S, Schneider L, Peters M, et al. Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2001; 12:1872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kausalya PJ, Amasheh S, Günzel D, et al. Disease-associated mutations affect intracellular traffic and paracellular Mg2+ transport function of Claudin-16. J Clin Invest 2006; 116:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godron A, Harambat J, Boccio V, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations. Clin J Am Soc Nephrol 2012; 7:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou J, Renigunta A, Konrad M, et al. Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. J Clin Invest 2008; 118:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konrad M, Schaller A, Seelow D, et al. Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 2006; 79:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meij IC, Saar K, van den Heuvel LP, et al. Hereditary isolated renal magnesium loss maps to chromosome 11q23. Am J Hum Genet 1999; 64:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meij IC, Koenderink JB, van Bokhoven H, et al. Dominant isolated renal magnesium loss is caused by misrouting of the Na(+),K(+)-ATPase gamma-subunit. Nat Genet 2000; 26:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meij IC, Koenderink JB, De Jong JC, et al. Dominant isolated renal magnesium loss is caused by misrouting of the Na+,K+-ATPase gamma-subunit. Ann N Y Acad Sci 2003; 986:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlingmann KP, Bandulik S, Mammen C, et al. Germline De Novo Mutations in ATP1A1 Cause Renal Hypomagnesemia, Refractory Seizures, and Intellectual Disability. Am J Hum Genet 2018; 103:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glaudemans B, van der Wijst J, Scola RH, et al. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. J Clin Invest 2009; 119:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adalat S, Woolf AS, Johnstone KA, et al. HNF1B mutations associate with hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol 2009; 20:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adalat S, Hayes WN, Bryant WA, et al. HNF1B Mutations Are Associated With a Gitelman-like Tubulopathy That Develops During Childhood. Kidney Int Rep 2019; 4:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kompatscher A, de Baaij JHF, Aboudehen K, et al. Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease. Kidney Int 2017; 92:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner CA. Disorders of renal magnesium handling explain renal magnesium transport. J Nephrol 2007; 20:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groenestege WM, Thébault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117:2260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrè S, de Baaij JH, Ferreira P, et al. Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting. J Am Soc Nephrol 2014; 25:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuiver M, Lainez S, Will C, et al. CNNM2, encoding a basolateral protein required for renal Mg2+ handling, is mutated in dominant hypomagnesemia. Am J Hum Genet 2011; 88:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goytain A, Quamme GA. Functional characterization of ACDP2 (ancient conserved domain protein), a divalent metal transporter. Physiol Genomics 2005; 22:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aglio LS, Stanford GG, Maddi R, et al. Hypomagnesemia is common following cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott VL, De Wolf AM, Kang Y, et al. Ionized hypomagnesemia in patients undergoing orthotopic liver transplantation: a complication of citrate intoxication. Liver Transpl Surg 1996; 2:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frisch LS, Mimouni F. Hypomagnesemia following correction of metabolic acidosis: a case of hungry bones. J Am Coll Nutr 1993; 12:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang HC, Chung DE, Kim DW, Kim HD. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia 2004; 45:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen EU, Campbell PG, Moosa GM. Hypomagnesemia and magnesium therapy in protein-calorie malnutrition. J Pediatr 1970; 77:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegler TR. Parenteral nutrition in the critically ill patient. N Engl J Med 2009; 361:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson FH, Hariri A, Farhi A, et al. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science 2004; 306:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitprija V. Altered fluid, electrolyte and mineral status in tropical disease, with an emphasis on malaria and leptospirosis. Nat Clin Pract Nephrol 2008; 4:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spichler A, Athanazio DA, Furtado J, et al. Case report: severe, symptomatic hypomagnesemia in acute leptospirosis. Am J Trop Med Hyg 2008; 79:915.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 829 Version 46.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6829504" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A high prevalence of hypomagnesemia and hypermagnesemia in hospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2914492" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Hypomagnesemia in patients in postoperative intensive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3407650" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2682045" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Magnesium homeostasis in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15665255" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Magnesium deficiency in critical illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20700443" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26685716" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Genome-wide association study reveals two loci for serum magnesium concentrations in European-American children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26058915" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Genetic loci for serum magnesium among African-Americans and gene-environment interaction at MUC1 and TRPM6 in European-Americans: the Atherosclerosis Risk in Communities (ARIC) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5637791" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Primary hypomagnesemia with secondary hypocalcemia in an infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9285786" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Familial hypomagnesemia maps to chromosome 9q, not to the X chromosome: genetic linkage mapping and analysis of a balanced translocation breakpoint.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12032568" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12032570" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15213256" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The transient receptor potential superfamily of ion channels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16107578" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21669885" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical and molecular characterization of Turkish patients with familial hypomagnesaemia: novel mutations in TRPM6 and CLDN16 genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14576148" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2407029" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Low intracellular magnesium in patients with acute pancreatitis and hypocalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22762246" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Systematic review: hypomagnesaemia induced by proton pump inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17065651" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Proton-pump inhibitors and hypomagnesemic hypoparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19920278" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hypomagnesemia induced by several proton-pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18221401" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Severe hypomagnesaemia in long-term users of proton-pump inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23325090" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Proton-pump inhibitor use is associated with low serum magnesium concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23664547" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25394217" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25268962" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23538697" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Proton pump inhibitors and hypomagnesemia: a rare but serious complication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23538697" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Proton pump inhibitors and hypomagnesemia: a rare but serious complication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1722865" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Renal magnesium wasting associated with therapeutic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29169235" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hypermagnesuria in Humans Following Acute Intravenous Administration of Digoxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1560382" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : An investigation of the acute effect of gentamicin on the renal handling of electrolytes in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15619138" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Magnesium and potassium homeostasis during cisplatin treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808192" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pathogenetic mechanisms of hypomagnesemia in alcoholic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8247056" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Renal tubular dysfunction in chronic alcohol abuse--effects of abstinence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639008" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Hypomagnesemia and diabetes mellitus. A review of clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8329802" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Magnesium and diabetes: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7549058" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hypomagnesemia in renal transplant patients: improvement over time and association with hypertension and cyclosporine levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19624560" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26449610" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14978156" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24335970" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Claudin-14 underlies Ca⁺⁺-sensing receptor-mediated Ca⁺⁺metabolism via NFAT-microRNA-based mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16797291" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Tacrolimus-associated hypomagnesemia in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11888584" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20970606" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Changes in magnesium and potassium homeostasis after conversion from a calcineurin inhibitor regimen to an mTOR inhibitor-based regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8760035" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9321915" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Phospholipase A2 is involved in mediating the effect of extracellular Ca2+ on apical K+ channels in rat TAL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22886306" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22373575" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Claudin-14 regulates renal Ca⁺⁺transport in response to CaSR signalling via a novel microRNA pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23283989" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Activation of the Ca(2+)-sensing receptor increases renal claudin-14 expression and urinary Ca(2+) excretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7267967" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The congenital "magnesium-losing kidney". Report of two patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8264518" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Magnesium metabolism in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5923603" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Hypomagnesemia of unknown etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1190259" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Hypomagnesemia due to renal disease of unknown etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4431494" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hypomagnesemia due to renal tubular defect in reabsorption of magnesium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12506158" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Recent advances in molecular genetics of hereditary magnesium-losing disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9481438" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Studies on the pathogenesis of hypokalemia in Gitelman's syndrome: role of bicarbonaturia and hypomagnesemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28381550" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinical and Genetic Spectrum of Bartter Syndrome Type 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19420365" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19289823" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25071208" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : KCNJ10 determines the expression of the apical Na-Cl cotransporter (NCC) in the early distal convoluted tubule (DCT1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7637271" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7742227" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Familial hypomagnesaemia--hypercalciuria leading to end-stage renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10809799" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Hypomagnesaemia-hypercalciuria-nephrocalcinosis: a report of nine cases and a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16705067" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Unusual clinical presentation and possible rescue of a novel claudin-16 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18003771" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7947033" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Pathophysiology of the renal acidification defect present in the syndrome of familial hypomagnesaemia-hypercalciuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10390358" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380823" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518780" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16528408" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Disease-associated mutations affect intracellular traffic and paracellular Mg2+ transport function of Claudin-16.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22422540" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: phenotype-genotype correlation and outcome in 32 patients with CLDN16 or CLDN19 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18188451" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17033971" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9915957" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Hereditary isolated renal magnesium loss maps to chromosome 11q23.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11062458" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Dominant isolated renal magnesium loss is caused by misrouting of the Na(+),K(+)-ATPase gamma-subunit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12763862" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Dominant isolated renal magnesium loss is caused by misrouting of the Na+,K+-ATPase gamma-subunit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30388404" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Germline De Novo Mutations in ATP1A1 Cause Renal Hypomagnesemia, Refractory Seizures, and Intellectual Disability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19307729" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19389850" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : HNF1B mutations associate with hypomagnesemia and renal magnesium wasting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31517149" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : HNF1B Mutations Are Associated With a Gitelman-like Tubulopathy That Develops During Childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28577853" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1βdrives autosomal dominant tubulointerstitial kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17918133" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Disorders of renal magnesium handling explain renal magnesium transport.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17671655" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24204001" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21397062" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : CNNM2, encoding a basolateral protein required for renal Mg2+ handling, is mutated in dominant hypomagnesemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15899945" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Functional characterization of ACDP2 (ancient conserved domain protein), a divalent metal transporter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863738" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Hypomagnesemia is common following cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1656826" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9346674" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Ionized hypomagnesemia in patients undergoing orthotopic liver transplantation: a complication of citrate intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8294727" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Hypomagnesemia following correction of metabolic acidosis: a case of hungry bones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15329077" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Early- and late-onset complications of the ketogenic diet for intractable epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5454720" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Hypomagnesemia and magnesium therapy in protein-calorie malnutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19741230" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Parenteral nutrition in the critically ill patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15498972" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A cluster of metabolic defects caused by mutation in a mitochondrial tRNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18227802" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Altered fluid, electrolyte and mineral status in tropical disease, with an emphasis on malaria and leptospirosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19052304" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Case report: severe, symptomatic hypomagnesemia in acute leptospirosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
